AAR MEETING WORKING GROUP MEDICAL DEFENSE AGAINST BIO WAR

File: 120396_sep96_decls39_0002.txt
Page: 0002
Total Pages: 2

Subject: AAR MEETING WORKING GROUP MEDICAL DEFENSE AGAINST BIO WAR       

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003203

Folder Title: AAR MEETING OF THE AD HOC WORKING GROUP FOR THE MEDICAL DEFENSE AGAINST BIOLOGICAL WARFARE-2    

Document Number:          1

Folder SEQ  #:        169





                                             UNCLASSIFIED



           product manufactured at these other locations and contirr
           bottle, label and test all materials in accordance with
           license. Two new fermentors have been installed at the
           Michigan facility. The first of three validation runs i
           expected to start the middle of next week. Due to a
           malfunction in a temperature regulator, two anthrax prod      I
           runs were unsuccessful. Data was presented on the curre@      I
           projected availability of both anthrax and botulinum vae




              e.        BW Challenge Studies. USAMRIID reported on
           continuing BW research efforts. Out of 10 primates who
           exposed to aerosolized anthrax and not treated, 9 died w      7
           to a days. of 10 primates only given vaccine, 8 died.
           primates given a 30-day therapy of penicillin, 2 died an      Is
           sick after 20 days. Three other groups (five in each) o
           primates who were treated with either ciprofloxacin,
           doxycycline, or doxycycline + vaccine were doing well.
           than 20 days after completing the antibiotic regimen, 13
           were alive (two died from causes unrelated to the anthra      k          m
           second cohort of 15 monkeys, in the same 3 groups, were       5
           da             completion of the antibiotics. scheduled





               f. (U) Ribavirin & Centoxin. Ribavirin and centox         re
           been delivered to Fort Detrick. on 24 October 1990, the       :t
           Shield Medical Issues Review and Ad Hoc Working Group me
           and discussed both these items. USAMRDC forwarded to th       I
           and Drug Administration (FDA) the necessary paperwork on
           use of these items in support of operation Desert Shield      k
           is expected to respond shortly with their approval. Due
           their cost, limited supply and importance, it was decide
  ribavirin and centoxin should be hand-carried into theat
           The individual who will hand-carry these items will also
           available to explain to medical personnel in-theater the
           indications for their use.

           S. The next meeting of the Ad Hoc Working Group is sche
           for 16 November 1990.





                                                           UNCLASSIFIED

Document 2 f:/Week-36/BX003203/AAR MEETING OF THE AD HOC WORKING GROUP FOR THE MEDICAL DEFENSE AGAINST BIOLOGICAL WARFARE-2/aar meeting working group medical defense agains:11089615092940
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003203
Unit = OTSG
Parent Organization = HSC
Folder Title = AAR MEETING OF THE AD HOC WORKING GROUP FOR THE MEDICAL DEFENSE AGAINST BIOLOGICAL WARFARE-2
Folder Seq # = 169
Subject = AAR MEETING WORKING GROUP MEDICAL DEFENSE AGAINS
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 08-NOV-1996